Literature DB >> 22622414

[Diagnosis and differential diagnosis of Graves' orbitopathy in MRI].

D Daubner1, S Spieth, K Engellandt, R von Kummer.   

Abstract

Imaging of Graves' orbitopathy (GO) includes radiological and nuclear medicine procedures. Depending on the method used they provide information about the distribution and activity of the disease. Magnetic resonance imaging (MRI) is not only a helpful tool for making the diagnosis it also enables differentiation of the active and inactive forms of GO due to intramuscular edema. The modality is therefore appropriate to evaluate the disease activity and the course of therapy. The disease leads to the typical enlargement of the muscle bodies of the extraocular muscles. The inferior rectus, medial rectus and levator palpebrae muscles are mostly involved. Signal changes of the intraconal and extraconal fat tissue are possible and a bilateral manifestation is common. The differential diagnosis includes inflammatory diseases and tumors, of which orbital pseudotumor (idiopathic, unspecific orbital inflammation), ocular myositis and orbital lymphoma are the most important. The specific patterns (localization, involvement of orbital structures and signal changes) can be differentiated by MRI.

Entities:  

Mesh:

Year:  2012        PMID: 22622414     DOI: 10.1007/s00117-012-2330-3

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  30 in total

Review 1.  Primary orbital lymphoma.

Authors:  Christopher M Nutting; Christopher D Jenkins; Andrew J Norton; Ian Cree; Geoffrey E Rose; P Nicholas Plowman
Journal:  Hematol J       Date:  2002

Review 2.  Graves' orbitopathy: current imaging procedures.

Authors:  Eberhard Kirsch; Beat Hammer; Georg von Arx
Journal:  Swiss Med Wkly       Date:  2009-10-31       Impact factor: 2.193

3.  A new MRI method for the quantitative evaluation of extraocular muscle size in thyroid ophthalmopathy.

Authors:  K Aydin; K Güven; S Sencer; A Cikim; N Gül; O Minareci
Journal:  Neuroradiology       Date:  2003-02-19       Impact factor: 2.804

4.  Modification of the classification of the eye changes of Graves' disease.

Authors:  S C Werner
Journal:  Am J Ophthalmol       Date:  1977-05       Impact factor: 5.258

Review 5.  [Ocular myositis].

Authors:  M Berkhoff; M Sturzenegger; G Schroth; C W Hess
Journal:  Nervenarzt       Date:  1997-10       Impact factor: 1.214

Review 6.  [Clinical and neuroradiological diagnostics of orbital tumors].

Authors:  C M Poloschek; W A Lagrèze; G J Ridder; C Hader
Journal:  Ophthalmologe       Date:  2011-06       Impact factor: 1.059

Review 7.  What is orbital pseudotumor?

Authors:  I Mombaerts; R Goldschmeding; R O Schlingemann; L Koornneef
Journal:  Surv Ophthalmol       Date:  1996 Jul-Aug       Impact factor: 6.048

Review 8.  Orbital pseudotumor.

Authors:  William M Mendenhall; Alan M Lessner
Journal:  Am J Clin Oncol       Date:  2010-06       Impact factor: 2.339

9.  Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach.

Authors:  M P Mourits; L Koornneef; W M Wiersinga; M F Prummel; A Berghout; R van der Gaag
Journal:  Br J Ophthalmol       Date:  1989-08       Impact factor: 4.638

10.  Ocular myositis: diagnostic assessment, differential diagnoses, and therapy of a rare muscle disease - five new cases and review.

Authors:  Benedikt G H Schoser
Journal:  Clin Ophthalmol       Date:  2007-03
View more
  2 in total

1.  Enhanced-depth optical coherence tomography for imaging horizontal rectus muscles in Graves' orbitopathy.

Authors:  Nathanael U Häner; Muriel Dysli; Mathias Abegg; Martin S Zinkernagel
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-06-07       Impact factor: 3.117

2.  Extraocular muscle sampled volume in Graves' orbitopathy using 3-T fast spin-echo MRI with iterative decomposition of water and fat sequences.

Authors:  Ludovico M Garau; Daniele Guerrieri; Flaminia De Cristofaro; Alice Bruscolini; Giuseppe Panzironi
Journal:  Acta Radiol Open       Date:  2018-06-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.